ReviewCancer immunology, immunotherapy : CII2019
T cell engineering for adoptive T cell therapy: safety and receptor avidity.
Review in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.Frontiers in immunology · 2020Trial
- The T Cell Receptor: Molecular Sensor, Therapeutic Mediator and Probabilistic Driver of Adaptive Immunity.Immunological reviews · 2026Review
- A New Approach to Examine Cell-Antibody Avidity with Surface Plasmon Resonance Imaging.Biosensors · 2025Article
- Characterization of Tumor Antigens from Multi-omics Data: Computational Approaches and Resources.Genomics, proteomics & bioinformatics · 2025Review
- Machine learning predictions of T cell antigen specificity from intracellular calcium dynamics.Science advances · 2024Article
- Article
- T Cell Receptor Chain Centricity: The Phenomenon and Potential Applications in Cancer Immunotherapy.International journal of molecular sciences · 2023Review
- Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.Cell reports. Medicine · 2023Article
- Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential.Molecular therapy. Methods & clinical development · 2023Article
- Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- A chimeric antigen receptor-based cellular safeguard mechanism for selectiveFrontiers in immunology · 2023Article
- Potential therapeutic targets of macrophages in inhibiting immune damage and fibrotic processes in musculoskeletal diseases.Frontiers in immunology · 2023Review
- CrossDome: an interactive R package to predict cross-reactivity risk using immunopeptidomics databases.Frontiers in immunology · 2023Article
- Unique features of the TCR repertoire of reactivated memory T cells in the experimental mouse tumor model.Computational and structural biotechnology journal · 2023Article
- Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia.Experimental hematology & oncology · 2022Review
- Droplet Microfluidics Enables Tracing of Target Cells at the Single-Cell Transcriptome Resolution.Bioengineering (Basel, Switzerland) · 2022Article
- Emerging Trends in Immunotherapy for Cancer.Diseases (Basel, Switzerland) · 2022Review
- Immune-based therapies in penile cancer.Nature reviews. Urology · 2022Review
- Strategies for Manipulating T Cells in Cancer Immunotherapy.Biomolecules & therapeutics · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Since the first bone marrow transplantation, adoptive T cell therapy (ACT) has developed over the last 80 years to a highly efficient and specific therapy for infections and cancer. Genetic engineering of T cells with antigen-specific receptors now provides the possibility of generating highly defined and efficacious T cell products. The high sensitivity of engineered T cells towards their targets, however, also bears the risk of severe off-target toxicities. Therefore, different safety strategies for engineered T cells have been developed that enable removal of the transferred cells in case of adverse events, control of T cell activity or improvement of target selectivity. Receptor avidity is a crucial component in the balance between safety and efficacy of T cell products. In clinical trials, T cells equipped with high avidity T cell receptor (TCR)/chimeric antigen receptor (CAR) have been mostly used so far because of their faster and better response to antigen recognition. However, over-activation can trigger T cell exhaustion/death as well as side effects due to excessive cytokine production. Low avidity T cells, on the other hand, are less susceptible to over-activation and could possess better selectivity in case of tumor antigens shared with healthy tissues, but complete tumor eradication may not be guaranteed. In this review we describe how 'optimal' TCR/CAR affinity can increase the safety/efficacy balance of engineered T cells, and discuss simultaneous or sequential infusion of high and low avidity receptors as further options for efficacious but safe T cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.